Black Rock Inc. Fate Therapeutics Inc Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Black Rock Inc. holds 10,116,106 shares of FATE stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,116,106
Previous 9,099,951
11.17%
Holding current value
$14.4 Million
Previous $66.8 Million
50.32%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$18.3 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$14.7 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$6.87 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.22 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$5.05 Million0.15% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $138M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...